Exelixis (EXEL) Shares Surge 11 Percent

Shares of Exelixis, Inc. (EXEL) are higher by nearly 11% in early morning trading on Thursday, as the stock continues to see gains following news that the FDA has granted Fast Track designation to cabozantinib for treatment of patients with advanced renal cell carcinoma (RCC) who have received one prior therapy. Cabozantinib is Exelixis’ lead […] View the full post at: Exelixis (EXEL) Shares Surge 11 Percent Related posts: Atlas Pipeline (APL) Shares Soar On Nat Gas Asset Sale Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock